Ascentage Pharma Reports Positive Clinical Data for Three Cancer Therapies at ASCO 2026
AAPG is trading near its 52-week low of $18.56 (3.7% above the low) on elevated volume (3.1× avg).
Summary
Ascentage Pharma presented encouraging clinical data for its MDM2-p53 inhibitor alrizomadlin and updated results for olverembatinib in multiple cancer indications at the ASCO 2026 Annual Meeting.
Key Events · Product Development and Regulatory · AAPG
-
Alrizomadlin (APG-115) in Pediatric Solid Tumors
First dataset showed preliminary antitumor activity and manageable tolerability, including a complete response in pediatric rhabdomyosarcoma, and encouraging objective response rates in combination with lisaftoclax.
-
Olverembatinib in CML-CP
Updated data demonstrated deepening responses over time, with 91.3% complete cytogenetic response and 60.9% major molecular response at cycle 24, supporting its role as a second-line therapy.
-
Olverembatinib + Blinatumomab in CML-LBP/Ph+ BCP-ALL
First international data showed encouraging clinical activity with 91% complete response/incomplete hematologic recovery and high rates of minimal residual disease negativity in difficult-to-treat leukemias.
-
ASCO 2026 Presentations
The company presented six studies involving three key assets at the 62nd ASCO Annual Meeting, marking its ninth consecutive appearance at the prominent oncology conference.
Analysis · AAPG · Life Sciences
This filing details positive clinical trial results for three of Ascentage Pharma's key drug candidates, including first-in-human data for alrizomadlin in pediatric solid tumors with a complete response, and strong efficacy for olverembatinib in CML-CP and in combination with blinatumomab for difficult-to-treat leukemias. These results, presented at a major oncology conference, provide further validation for the company's pipeline and address significant unmet medical needs, potentially boosting investor confidence while the stock trades near its 52-week low.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AAPG was trading at $19.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.56 to $48.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.